A Dose Finding Study (Phase I) of the Combination of ZD1839 (Iressa) and an Oral Formulation of Irinotecan (Camptosar) in Children With Refractory Solid Tumors.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2014
At a glance
- Drugs Gefitinib (Primary) ; Irinotecan (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 31 Aug 2018 Biomarkers information updated
- 16 Apr 2012 Actual patient number is 19 according to ClinicalTrials.gov.
- 16 Apr 2012 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.